In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer

Experimental Cell Research

Volumn 318, Issue 19, 2012, Pages 2507-2519

  Windus, Louisa C E ^a   Kiss, Debra L ^a   Glover, Tristan ^a   Avery, Vicky M ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

3D models; Chemokines; EMT; Integrins; Prostate Cancer

Indexed keywords

BETA1 INTEGRIN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; NERVE CELL ADHESION MOLECULE; VIMENTIN;

ARTICLE; CANCER GROWTH; CELL STRUCTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; THREE DIMENSIONAL IMAGING; UPREGULATION;

EID: 84866343225     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.07.013     Document Type: Article

References (46)

1. Harma V., Virtanen J., Makela R., Happonen A., Mpindi J.P., Knuuttila M., Kohonen P., Lotjonen J., Kallioniemi O., Nees M. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010, 5(5):e10431.
2. Nyga A., Cheema U., Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun. Signal 2011, 5(3):239-248.
3. Tamburrino L., Salvianti F., Marchiani S., Pinzani P., Nesi G., Serni S., Forti G., Baldi E. Androgen receptor (AR) expression in prostate cancer and progression of the tumor: lessons from cell lines, animal models and human specimens. Steroids 2012, 18(13):3532-3540.
4. Knox J.D., Cress A.E., Clark V., Manriquez L., Affinito K.S., Dalkin B.L., Nagle R.B. Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am. J. Pathol. 1994, 145(1):167-174.
5. Bonkhoff H., Stein U., Remberger K. Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum. Pathol. 1993, 24(3):243-248.
6. Murant S.J., Handley J., Stower M., Reid N., Cussenot O., Maitland N.J. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur. J. Cancer 1997, 33(2):263-271.
7. Lang S.H., Hyde C., Reid I.N., Hitchcock I.S., Hart C.A., Bryden A.A., Villette J.M., Stower M.J., Maitland N.J. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002, 52(4):253-263.
8. Wang J., Krill D., Torbenson M., Wang Q., Bisceglia M., Stoner J., Thomas A., DeFlavia P., Dhir R., Becich M.J. Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol. Res. 2000, 28(5):308-315.
9. Wang J., Loberg R., Taichman R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006, 25(4):573-587.
10. Gravdal K., Halvorsen O.J., Haukaas S.A., Akslen L.A. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 2007, 13(23):7003-7011.
11. Thompson E.W., Newgreen D.F., Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Res. 2005, 65(14):5991-5995. discussion 5995.
12. Chu P.G., Weiss L.M. Keratin expression in human tissues and neoplasms. Histopathology 2002, 40(5):403-439.
13. Cheng L., Nagabhushan M., Pretlow T.P., Amini S.B., Pretlow T.G. Expression of E-cadherin in primary and metastatic prostate cancer. Am. J. Pathol. 1996, 148(5):1375-1380.
14. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62(6):1832-1837.
15. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54(20):5474-5478.
16. Salic A., Mitchison T.J. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc. Natl. Acad. Sci. USA 2008, 105(7):2415-2420.
17. Tilley W.D., Bentel J.M., Aspinall J.O., Hall R.E., Horsfall D.J. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids 1995, 60(1):180-186.
18. Tilley W.D., Wilson C.M., Marcelli M., McPhaul M.J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 1990, 50(17):5382-5386.
19. Migliaccio A., Castoria G., Auricchio F. Analysis of androgen receptor rapid actions in cellular signaling pathways: receptor/Src association. Methods Mol. Biol. 2011, 776:361-370.
20. Unni E., Sun S., Nan B., McPhaul M.J., Cheskis B., Mancini M.A., Marcelli M. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 2004, 64(19):7156-7168.
21. Matesz C., Modis L., Halasi G., Szigeti Z.M., Felszeghy S., Bacskai T., Szekely G. Extracellular matrix molecules and their possible roles in the regeneration of frog nervous system. Brain Res. Bull. 2005, 66(4-6):526-531.
22. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol. 2010, 28(3):125-133.
23. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130(4):601-610.
24. Bussemakers M.J., Van Bokhoven A., Tomita K., Jansen C.F., Schalken J.A. Complex cadherin expression in human prostate cancer cells. Int. J. Cancer 2000, 85(3):446-450.
25. Umbas R., Isaacs W.B., Bringuier P.P., Schaafsma H.E., Karthaus H.F., Oosterhof G.O., Debruyne F.M., Schalken J.A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994, 54(14):3929-3933.
26. Tomita K., van Bokhoven A., van Leenders G.J., Ruijter E.T., Jansen C.F., Bussemakers M.J., Schalken J.A. Cadherin switching in human prostate cancer progression. Cancer Res. 2000, 60(13):3650-3654.
27. Daniels D.L., Eklof Spink K., Weis W.I. beta-catenin: molecular plasticity and drug design. Trends Biochem. Sci. 2001, 26(11):672-678.
28. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4(2):118-132.
29. Derycke L.D., Bracke M.E. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int. J. Dev Biol. 2004, 48(5-6):463-476.
30. Okera M., Bae K., Bernstein E., Cheng L., Lawton C., Wolkov H., Pollack A., Dicker A., Sandler H., Sweeney C.J. Evaluation of nuclear factor kappaB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int. 2011, 108(2b):E51-E58.
31. Sun Y.X., Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M., Rubin M.A., Pienta K.J., Taichman R.S. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell Biochem. 2003, 89(3):462-473.
32. Howe G., Addison C. beta1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy. Cell Adhes. Migr. 2012, 6:71-77.
33. Zhang X., Fournier M.V., Ware J.L., Bissell M.J., Yacoub A., Zehner Z.E. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol. Cancer Ther. 2009, 8(3):499-508.
34. Garlick D.S., Li J., Sansoucy B., Wang T., Griffith L., Fitzgerald T., Butterfield J., Charbonneau B., Violette S.M., Weinreb P.H., Ratliff T.L., Liao C.P., Roy-Burman P., Vietri M., Lian J.B., Stein G.S., Altieri D.C., Languino L.R. Alpha(V)beta(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. Am. J. Transl. Res. 2012, 4(2):165-174.
35. Culig Z., Klocker H., Eberle J., Kaspar F., Hobisch A., Cronauer M.V., Bartsch G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993, 22(1):11-22.
36. Alimirah F., Chen J., Basrawala Z., Xin H., Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 2006, 580(9):2294-2300.
37. Peehl D.M., Wong S.T., Bazinet M., Stamey T.A. In vitro studies of human prostatic epithelial cells: attempts to identify distinguishing features of malignant cells. Growth Factors 1989, 1(3):237-250.
38. Sun M., Yang L., Feldman R.I., Sun X.M., Bhalla K.N., Jove R., Nicosia S.V., Cheng J.Q. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J. Biol. Chem. 2003, 278(44):42992-43000.
39. Ueda T., Bruchovsky N., Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 2002, 277(9):7076-7085.
40. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25(2):276-308.
41. Zhu M.L., Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 2008, 15(4):841-849.
42. Basrawala Z., Alimirah F., Xin H., Mohideen N., Campbell S.C., Flanigan R.C., Choubey D. Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Oncogene 2006, 25(19):2812-2817.
43. Araujo J.C., Poblenz A., Corn P., Parikh N.U., Starbuck M.W., Thompson J.T., Lee F., Logothetis C.J., Darnay B.G. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol. Ther. 2009, 8(22):2153-2159.
44. Hatzoglou A., Kampa M., Kogia C., Charalampopoulos I., Theodoropoulos P.A., Anezinis P., Dambaki C., Papakonstanti E.A., Stathopoulos E.N., Stournaras C., Gravanis A., Castanas E. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J. Clin. Endocrinol. Metab. 2005, 90(2):893-903.
45. Kampa M., Papakonstanti E.A., Hatzoglou A., Stathopoulos E.N., Stournaras C., Castanas E. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J. 2002, 16(11):1429-1431.
46. Papakonstanti E.A., Kampa M., Castanas E., Stournaras C. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol. Endocrinol. 2003, 17(5):870-881.